Park Ha Biological Technology Co., Ltd. (BYAH) Key Metrics
BYAH valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $42.9M
- Enterprise value
- −$3.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 16.9
- Price / book
- 0.4
- EV / EBITDA
- 15.5
- Dividend yield
- —
- Beta
- —
BYAH key metrics, FY2021–FY2025
Fiscal year ended October 31, 2025 · U.S. dollarsBYAH returns How much profit the business earns on the capital it uses.
BYAH financial health Debt, liquidity and how easily interest is covered.
BYAH efficiency & capital use Working capital cycle and where the cash goes.
BYAH returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BYAH debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BYAH key metrics
FY2021–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Valuation | |||||
| Share price at fiscal year-end | $150.00 | — | — | — | — |
| Returns & profitability | |||||
| Return on equity (ROE) | −885.8% | 38.0% | 146.6% | — | — |
| Return on invested capital (ROIC) | — | 92.1% | — | — | — |
| Return on assets (ROA) | −539.3% | 17.9% | 35.6% | 12.3% | −81.6% |
| Return on tangible assets | −409.8% | 15.6% | 37.8% | 7.6% | −81.6% |
| Free cash flow margin | −0.1% | 36.7% | 4.2% | 74.5% | −54.9% |
| Income quality (OCF / net income) | — | 2.01 | 0.15 | 7.54 | — |
| Financial health | |||||
| Total debt | $180,169 | $70,318 | $31,462 | $26,194 | $35,203 |
| Cash & short-term investments | $3.8M | $547,498 | $1.0M | $574,711 | $72,686 |
| Net debt | −$3.6M | −$477,180 | −$1.0M | −$548,517 | −$37,483 |
| Debt / equity | 0.05 | 0.05 | 0.03 | 0.17 | — |
| Debt / assets | 0.03 | 0.02 | 0.01 | 0.01 | 0.06 |
| Net debt / EBITDA | — | −0.58 | −0.83 | −2.49 | — |
| Current ratio | 2.92 | 1.87 | 1.75 | 0.96 | 0.41 |
| Quick ratio | 2.88 | 1.82 | 1.67 | 0.92 | 0.14 |
| Interest coverage | — | — | — | — | -419.6 |
| Working capital | $3.6M | $1.3M | $933,244 | −$103,814 | −$682,949 |
| Invested capital | $387,346 | $1.0M | $10,301 | −$398,240 | −$615,668 |
| Tangible asset value | $4.0M | $1.5M | $1.0M | $140,928 | −$578,185 |
| Net current asset value | $3.5M | $1.3M | $923,752 | −$103,814 | −$698,808 |
| Capital allocation | |||||
| Capex / revenue | 3.5% | 3.6% | 0.9% | 0.6% | 1.4% |
| Capex / operating cash flow | 103.5% | 8.9% | 17.9% | 0.8% | — |
| Capex / depreciation | 0.81 | 3.77 | 1.13 | 0.39 | 0.33 |
| Stock-based compensation / revenue | 953.3% | 0.0% | 0.0% | — | — |
| R&D / revenue | 9.4% | 1.5% | 1.3% | 3.2% | 5.6% |
| SG&A / revenue | 1,034.1% | 49.4% | 31.9% | 59.7% | 80.8% |
| Efficiency | |||||
| Days sales outstanding | 174.4 | 139.5 | 166.0 | 152.6 | 31.2 |
| Days of inventory on hand | 199.9 | 156.4 | 111.5 | 147.2 | 371.3 |
| Days payables outstanding | 46.2 | 206.7 | 191.8 | 78.5 | 104.8 |
| Cash conversion cycle (days) | 328.0 | 89.2 | 85.7 | 221.3 | 297.7 |
| Receivables turnover | 2.09 | 2.62 | 2.20 | 2.39 | 11.68 |
| Payables turnover | 7.90 | 1.77 | 1.90 | 4.65 | 3.48 |
| Inventory turnover | 1.83 | 2.33 | 3.27 | 2.48 | 0.98 |
| Asset turnover | 0.56 | 0.89 | 1.03 | 1.23 | 1.57 |
| Average receivables | $1.2M | $910,221 | $1.1M | $802,682 | $79,707 |
| Average payables | $18,041 | $110,612 | $163,439 | $109,532 | $89,341 |
| Average inventory | $78,042 | $83,678 | $95,020 | $205,341 | $316,512 |
| Intangibles / total assets | 0.1% | 0.2% | 0.4% | 0.4% | 0.0% |
Computed from BYAH's annual financial statements (latest annual report filed October 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BYAH valuation and financial ratios
Park Ha Biological Technology earned a return on equity of −885.8% in fiscal 2025. It ended the year with $0.2 million of debt and $3.8 million in cash and short-term investments, a net cash position of $3.6 million.
See the BYAH income statement, the BYAH chart for price history, or the BYAH stock overview for the latest quote and news.
BYAH key metrics FAQ
What is Park Ha Biological Technology's return on equity?
Park Ha Biological Technology's return on equity (ROE) was −885.8% in fiscal 2025: net income of -$24.4 million on average shareholders' equity of $2.8 million.
How much debt does Park Ha Biological Technology have?
Park Ha Biological Technology had total debt of $0.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.05 and more cash than debt.
What is Park Ha Biological Technology's current ratio?
Park Ha Biological Technology's current ratio was 2.92 at the end of fiscal 2025: current assets were 2.92 times current liabilities.